| Indicator | Current Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥1502.6B | ¥1431.9B | +4.9% |
| Operating Income / Operating Profit | ¥104.2B | ¥93.6B | +11.3% |
| Ordinary Income | ¥110.1B | ¥99.7B | +10.5% |
| Net Income / Net Profit | ¥71.0B | ¥59.7B | +18.9% |
| ROE | 5.4% | 4.5% | - |
The FY2024 financial results closed with Revenue ¥1,502.6B (YoY +¥70.7B +4.9%), Operating Income ¥104.2B (YoY +¥10.6B +11.3%), Ordinary Income ¥110.1B (YoY +¥10.4B +10.5%), and Net Income attributable to owners of the parent ¥71.0B (YoY +¥11.3B +18.9%), delivering growth in both top and bottom lines. Revenue progressed steadily reflecting firm clinical testing demand, and Operating Income achieved double-digit growth driven by an improvement in gross margin (32.0%→32.4% +40bp) and controlled SG&A. At the Ordinary Income level, increases in interest and dividend income contributed, and Net Income rose substantially YoY (+18.9%) due to recording Special Gains of ¥13.6B including ¥12.0B gain on sale of fixed assets. Operating margin was 6.9% (improved +0.4pt from 6.5% prior year), and Net Profit Margin was 4.7% (improved +0.6pt), indicating expanding margins.
【Revenue】 Revenue of ¥1,502.6B grew YoY +4.9% (+¥70.7B). Growth was led by steady increases in outsourced clinical testing volumes in the core testing business and an improved test mix (expansion of higher value-added tests). Gross profit was ¥486.9B (gross margin 32.4%), up ¥28.3B YoY, with gross margin improving +40bp from 32.0% a year earlier. Cost of sales ratio improved to 67.6% YoY, likely reflecting improved test processing efficiency and absorption of fixed costs.
【Profitability】 Operating Income was ¥104.2B (YoY +11.3%), with an Operating Margin of 6.9% (up +0.4pt from 6.5% prior year). SG&A was ¥382.7B (SG&A ratio 25.5%), up ¥16.8B YoY, but roughly in line with revenue growth, so scale benefits were limited. Ordinary Income was ¥110.1B (YoY +10.5%), with non-operating income of ¥7.6B (including interest income ¥1.1B and dividend income ¥1.4B) contributing, offset by non-operating expenses of ¥1.7B (including interest expense ¥1.2B), yielding a net addition of ¥5.9B. Special gains totaled ¥13.6B, mainly from gain on sale of fixed assets ¥12.0B, while special losses were ¥3.9B, mainly impairment losses ¥3.7B, resulting in a net positive ¥9.7B that boosted final profit. Profit before income taxes was ¥119.9B (YoY +23.9%), and after deducting income taxes of ¥39.8B, Net Income attributable to owners of the parent was ¥71.0B (YoY +18.9%), concluding with growth in both revenue and profit.
【Profitability】Operating Margin was 6.9% (improved +0.4pt from 6.5% prior year), Net Profit Margin was 4.7% (improved +0.5pt from 4.2% prior year), indicating expanding margins. ROE was 5.4%, improved from 4.9% prior year, but profit levels remain restrained relative to the strength of equity, indicating room to further improve capital efficiency. 【Cash Quality】Operating Cash Flow (OCF) was ¥207.2B, 2.9x Net Income of ¥71.0B, and the OCF/EBITDA ratio was 1.06x (EBITDA = Operating Income ¥104.2B + Depreciation ¥91.2B = ¥195.4B), indicating healthy cash generation. The accrual ratio was -7.0%, low, suggesting strong cash backing of earnings. 【Investment Efficiency】Capital expenditures were ¥87.5B, with an investment/depreciation ratio of 0.96x relative to Depreciation ¥91.2B, indicating investment focused on renewal; Construction in progress rose to ¥57.9B (from ¥32.7B prior year, +77%), implying expected capacity expansion and efficiency gains upon commissioning. 【Financial Soundness】Equity Ratio was 72.1% (slight decrease from 73.1% prior year), remaining high, and interest-bearing debt consisted only of short-term borrowings ¥9B, with a Debt/EBITDA ratio of 0.05x, extremely low. Current Ratio was 249%, Quick Ratio 248%, indicating sufficient short-term liquidity. Days Sales Outstanding (DSO) is approximately 65 days, somewhat long, suggesting room to optimize receivables collection.
Operating Cash Flow was ¥207.2B (YoY +31.0%). From an operating cash subtotal of ¥236.6B, movements in working capital (inventory -¥1.5B, accounts receivable -¥0.1B, accounts payable +¥5.1B, net +¥3.5B) and corporate tax payments -¥34.2B led to the closing figure. Working capital changes were minor; a slight increase in inventory (¥3.3B, from ¥2.5B prior year +32.5%) is presumed to reflect accumulation of testing materials. Investing Cash Flow was -¥76.9B, mainly due to capital expenditures -¥87.5B, partly offset by proceeds from sale of fixed assets ¥21.98B, and including intangible asset acquisitions -¥13.74B, reducing net outflow substantially from -¥167.9B prior year. Financing Cash Flow was -¥123.5B, driven by shareholder returns: dividend payments -¥49.8B and share buybacks -¥53.8B. Free Cash Flow was ¥130.3B (OCF ¥207.2B + Investing CF -¥76.9B), with FCF coverage of dividends and buybacks totaling ¥103.6B at 1.26x, sufficiently covering shareholder returns. Cash and deposits were ¥680.3B (slight increase from ¥675.6B prior year), with net increase of only ¥6.7B.
Overall quality of earnings is generally good, but attention is warranted to the significant contribution from one-off items. Non-operating income ¥7.6B (0.5% of Revenue) was mainly financial income such as dividend income ¥1.4B and interest income ¥1.1B, exceeding non-operating expenses ¥1.7B (mainly interest expense ¥1.2B), resulting in net financial income +¥5.9B that supported Ordinary Income. Special gains were ¥13.6B (mainly gain on sale of fixed assets ¥12.0B) and special losses were ¥3.9B (mainly impairment losses ¥3.7B), netting +¥9.7B that boosted Net Income. One-off items (net special gains/losses) accounted for about 13.7% of Net Income ¥71.0B, so a reversal is expected next fiscal year. Given that OCF is 2.9x Net Income, OCF/EBITDA is 1.06x, and accrual ratio is -7.0%, operating-level profits have strong cash backing and high quality. The divergence between Ordinary Income ¥110.1B and Net Income ¥71.0B reflects taxes of ¥39.1B plus the impact of net special items, and the Ordinary Income level appears to be an appropriate measure of sustainable core earnings.
Full Year guidance anticipates Revenue ¥1,550.0B (YoY +3.2%), Operating Income ¥105.0B (YoY +0.8%), Ordinary Income ¥110.0B (YoY -0.1%), and Net Income attributable to owners of the parent ¥70.0B. Actual results were Revenue ¥1,502.6B (96.9% of forecast), Operating Income ¥104.2B (99.3%), Ordinary Income ¥110.1B (100.1%), and Net Income ¥71.0B (101.4%); Revenue was slightly short, but profits were on or near plan. The shortfall in Revenue is presumed due to timing of testing demand, but Operating Income met the plan due to improved gross margin and controlled SG&A. Ordinary Income exceeded forecast due to higher non-operating income, and Net Income exceeded forecast due to recording of special gains. Next fiscal year, a reversal of one-off gains is expected, and steady buildup of Revenue (testing volumes and mix improvement) plus continued cost efficiency will be key to achieving guidance.
Annual dividend was ¥125 (interim ¥60, year-end ¥65), with a Payout Ratio of 74.7%. Dividends increased by ¥75 from prior year dividend of ¥50, indicating a strengthening stance on dividend policy. Share buybacks were recorded as -¥53.8B in the Cash Flow Statement, and combined with dividend payments -¥49.8B, total shareholder returns amounted to ¥103.6B. Total Return Ratio (dividends + buybacks ÷ Net Income) was 146%, exceeding Net Income, but FCF coverage versus Free Cash Flow ¥130.3B was 1.26x, so this fiscal year was sufficiently funded from internal cash. Given cash and deposit balance ¥680.3B and high OCF ¥207.2B, maintaining current dividend levels appears sustainable. However, the Payout Ratio of 74.7% exceeds the desirable level (≤60%), so from next fiscal year onward, adjusting total return balance (dividend stability and flexible share buybacks) while considering reversal of one-off gains would be appropriate.
Revision risk to national medical fees: If official prices for clinical tests are revised downward, test unit prices would be directly pressured and margins affected. While gross margin improved to 32.4% YoY, absorption capacity for price declines is limited.
Risk of prolonged receivables collection: Accounts receivable ¥268.3B, DSO approx. 65 days, somewhat long; payment delays or bad debts at medical institutions could strain working capital and impair quality of OCF. The increase in allowance for doubtful accounts to ¥60M (from ¥23M prior year, +161%) suggests early signs.
Dependence on one-off items: Gain on sale of fixed assets ¥12.0B accounts for about 16.9% of Net Income ¥71.0B, posing a risk of variability in final profit if this does not recur. The Ordinary Income level of ¥110.1B should be emphasized as the sustainable earnings base.
Profitability & Returns
| Indicator | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 6.9% | 8.1% (3.6%–16.0%) | -1.2pt |
| Net Profit Margin | 4.7% | 5.8% (1.2%–11.6%) | -1.1pt |
Both Operating Margin and Net Profit Margin are slightly below the industry median, indicating room for profitability improvement.
Growth & Capital Efficiency
| Indicator | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 4.9% | 10.1% (1.7%–20.2%) | -5.2pt |
Revenue growth rate is below the industry median, indicating room to accelerate growth.
※Source: Company compilation
Continued improvement in core earning power is key: Gross margin improved +40bp from 32.0% to 32.4%, and Operating Margin rose from 6.5% to 6.9%. Improved test mix and processing efficiency contributed, and it will be important to monitor whether expansion of higher value-added tests and absorption of fixed costs continue to drive margin expansion.
Strong cash generation and capacity for capital returns: OCF ¥207.2B and Free Cash Flow ¥130.3B are ample, and FCF coverage of dividends + buybacks ¥103.6B is secured at 1.26x. With cash and deposits ¥680.3B and interest-bearing debt ¥9B, the financial position is extremely conservative, enabling stable dividends and flexible capital returns.
Reversal of one-off gains and opportunity to improve capital efficiency: Gain on sale of fixed assets ¥12.0B has boosted Net Income, so final profit may be impacted by a reversal next fiscal year. ROE 5.4% remains low versus peers, and raising capital efficiency through more efficient growth investments or optimizing capital return policy is key to mid-term shareholder value improvement.
This report is an earnings analysis document automatically generated by AI analyzing XBRL financial statement data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by the Company based on public financial statements. Investment decisions are your own responsibility; consult a professional advisor as needed.